Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKesson
McKinsey
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRIZOTINIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Crizotinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00939770 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2009-09-01 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT00939770 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting Children's Oncology Group Phase 1/Phase 2 2009-09-01 RATIONALE: Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of crizotinib and to see how well it works in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma.
NCT01082380 Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers Completed Pfizer Phase 1 2010-03-01 The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
NCT01121588 An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Active, not recruiting Pfizer Phase 1 2011-03-01 This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
NCT01125904 A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers Completed Pfizer Phase 1 2010-06-01 An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being tested for its' palatability in adults.
NCT01147055 Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers Completed Pfizer Phase 1 2010-07-01 The purpose of this study is to estimate the effect of multiple doses of Rifampin on the single dose pharmacokinetics of Crizotinib in healthy volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Crizotinib

Condition Name

Condition Name for Crizotinib
Intervention Trials
Non-small Cell Lung Cancer 23
Healthy 10
Carcinoma, Non-Small-Cell Lung 7
Lung Cancer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crizotinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 56
Lung Neoplasms 46
Lymphoma 14
Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crizotinib

Trials by Country

Trials by Country for Crizotinib
Location Trials
United States 600
Italy 78
Japan 63
China 56
Spain 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crizotinib
Location Trials
Texas 28
California 28
Florida 25
Massachusetts 24
Ohio 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crizotinib

Clinical Trial Phase

Clinical Trial Phase for Crizotinib
Clinical Trial Phase Trials
Phase 4 3
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crizotinib
Clinical Trial Phase Trials
Recruiting 53
Not yet recruiting 25
Active, not recruiting 22
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crizotinib

Sponsor Name

Sponsor Name for Crizotinib
Sponsor Trials
Pfizer 46
National Cancer Institute (NCI) 11
Hoffmann-La Roche 8
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crizotinib
Sponsor Trials
Other 120
Industry 95
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
Mallinckrodt
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.